Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases

Abstract

The preset invention relates to combination pharmaceutical composition comprising an activated-potentiated from of an antibody to gamma interferon, and an activated-potentiated form of an antibody to S-100 protein and method of treating multiple sclerosis and other neurodegenerative diseases, as well as the diseases and conditions associated with neuroinfections.

1 - 23 . (canceled) 
     
     
         24 . A method of treating neuroinfection, said method comprising administering to a patient in need thereof, substantially at the same time a) an activated-potentiated form of an antibody to gamma interferon and b) an activated-potentiated form of an antibody to S-100 protein. 
     
     
         25 . The method of  claim 24 , wherein said activated-potentiated form of an antibody to gamma interferon and said activated-potentiated form of an antibody to S-100 protein are administered in the form of a combined pharmaceutical composition. 
     
     
         26 . A method of treating neuroinfection, said method comprising administering to a patient in need thereof an activated-potentiated form of an antibody to S-100 protein. 
     
     
         27 . The method of  claim 25 , wherein the combined pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage form being administered from once daily to four times daily. 
     
     
         28 . The method of  claim 25 , wherein the combined pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage form being administered twice daily. 
     
     
         29 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to gamma interferon is to the entire gamma interferon having SEQ ID NO 1 or SEQ ID NO 2. 
     
     
         30 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to gamma interferon is to a fragment of gamma interferon having sequences selected from group consisting of SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12 and SEQ ID NO. 13. 
     
     
         31 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to S-100 protein is to the entire bovine S-100 protein. 
     
     
         32 . The method of  claim 24 , wherein the activated-potentiated form of an antibody is to the S-100 protein having the amino acid sequence of SEQ ID NO 14. 
     
     
         33 . The method of  claim 24 , wherein the activated-potentiated form of an antibody is to the S-100 protein having the amino acid sequence of SEQ ID NO 17. 
     
     
         34 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to gamma interferon is in the form of a mixture of C12, C30, and C50 homeopathic dilutions impregnated onto a solid carrier and the activated-potentiated form of an antibody to S-100 protein is in the form of mixture of C12, C30, and C50 homeopathic dilutions subsequently impregnated onto the solid carrier. 
     
     
         35 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to gamma interferon is in the form of a mixture of C12, C30, and C200 homeopathic dilutions impregnated onto a solid carrier and the activated-potentiated form of an antibody to S-100 protein is in the form of mixture of C12, C30, and C200 homeopathic dilutions subsequently impregnated onto the solid carrier. 
     
     
         36 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to S-100 protein is in the form of mixture of C12, C30, and C50 homeopathic dilutions impregnated onto a solid carrier and the activated-potentiated form of an antibody to gamma interferon is in the form of mixture of C12, C30, and C50 homeopathic dilutions subsequently impregnated onto the solid carrier. 
     
     
         37 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to S-100 protein is in the form of mixture of C12, C30, and C200 homeopathic dilutions impregnated onto a solid carrier and the activated-potentiated form of an antibody to gamma interferon is in the form of mixture of C12, C30, and C200 homeopathic dilutions subsequently impregnated onto the solid carrier. 
     
     
         38 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to gamma interferon is a monoclonal, polyclonal or natural antibody. 
     
     
         39 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to gamma interferon is prepared by successive centesimal dilutions coupled with shaking of every dilution. 
     
     
         40 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to S-100 protein is a monoclonal, polyclonal or natural antibody. 
     
     
         41 . The method of  claim 24 , wherein the activated-potentiated form of an antibody to S-100 protein is prepared by successive centesimal dilutions coupled with shaking of every dilution.